What are the indications for Seleniso (Silvio)?

Selinexor (Selinexor) is a selective inhibitor of nuclear export (Selective Inhibitor of Nuclear Export, SINE), mainly used to treat specific types of hematological malignancies. Its indications mainly include multiple myeloma (MM) and relapsed/refractory diffuse large B-cell lymphoma (Diffuse Large B-cell Lymphoma, DLBCL), etc. The following is a detailed introduction to its indications:

1. Multiple myeloma (MM): Multiple myeloma is a malignant tumor that mainly originates from plasma cells in the bone marrow. Selinesol (Silvio) As a targeted therapy drug, it is approved for the treatment of multiple myeloma, especially playing an important role in relapsed /refractory disease. Selinisol (Silvio) may be an effective treatment option for adult patients who have received at least one prior line of therapy and are refractory to proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies.

2. Recurrent/Refractory diffuse largeB cell lymphoma (DLBCL): Diffuse large BB cell lymphoma is a highly heterogeneous malignant lymphoma that is common in a subtype of BB cell lymphoma. Selinisol (Sivio) is also approved as a new treatment option for patients whose disease relapses or is refractory to treatment. It may be used in combination with other drugs to improve patient prognosis and survival.

3. Other indications in clinical trials: In addition, selinesol (Silvio) may also be used in clinical trials to treat other types of hematological malignancies, such as chronic lymphocytic leukemia (Chronic Lymphocytic Leukemia, CLL) and acute myeloid leukemia (Acute Myeloid Leukemia, AML), etc. The results of these trials will further validate the efficacy and safety of selinesol (Silvio) in these diseases.

In summary,Seliniso (Silvio) as a targeted therapy drug, is suitable for the treatment of specific types of hematological malignancies such as multiple myeloma and relapsed/refractory diffuse largeB cell lymphoma. It could become an important treatment option for patients whose disease remains difficult to control despite multiple treatments.